Patent Assignment
Reel/Frame 044552/0694
Release of Security Interest
Recorded: 2017-11-30
Pages: 17
Assignor
U.S. BANK NATIONAL ASSOCIATION
Executed: 2017-11-20
Assignee
SUPERNUS PHARMACEUTICALS, INC.
1550 EAST GUDE DRIVE, ROCKVILLE, MARYLAND, 20850
Covered Properties
(67)
Soluble Form Osmotic Dose Delivery System
Patent:
6,110,498 →
Application:
08/954,947 →
Solid Oral Dosage Form
Patent:
6,793,934 →
Application:
09/457,248 →
Soluble form osmotic dose delivery system
Patent:
6,284,276 →
Application:
09/613,202 →
Soluble form osmotic dose delivery system
Patent:
6,361,796 →
Application:
09/634,224 →
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Patent:
6,287,599 →
Application:
09/741,548 →
System for Osmotic Delivery of Pharmaceutically Active Agents
Sustained Release Pharmaceutical Dosage Forms with Minimized Ph Dependent Dissolution Profiles
Soluble Form Osmotic Dose Delivery System
Use of Molindone to Treat Oppositional Defiant Disorder and Conduct Disorder
Soluble Form Osmotic Dose Delivery System
Treatment of Oppositional Defiant Disorder and Conduct Disorder with 5-Aminoalkyl-4,5,6,7-Tetrahydro-4-Oxyindolones
Drug formulations having reduced abuse potential
Osmotic Delivery of Therapeutic Compounds by Solubility Enhancement
Use of a Mixture of Two or More Enteric Materials to Regulate Drug Release via Membrane or Matrix for Systemic Therapeutics
Controlled Release Compositions of Gamma-Hydroxybutyrate
Less Abusable Pharmaceutical Preparations
Osmotic drug delivery system
Modified-Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Topiramate Compositions and Methods of Enhancing Its Bioavailability
Sustained-Release Formulations of Topiramate
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Method of Treating Seizures Using Modified Release Formulations of Oxcarbazepine
Controlled Release Formulations of Alprazolam
Application:
12/436,954 →
Publication:
US 2009/0280176
Use of Isoindoles for the Treatment of Neurobehavioral Disorders
Application:
12/477,665 →
Publication:
US 2009/0318520
Sustained-Release Formulations of Topiramate
Sustained-release formulations of topiramate
Use of a Mixture of Two or More Enteric Materials to Regulate Drug Release via Membrance or Matrix for Systemic Therapeutics
Stabilized Formulations of Cns Compounds
Methods for Producing Viloxazine Salts and Novel Polymorphs Thereof
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Controlled Release Compositions of Gamma-Hydroxybutyrate
Sustained-Release Formulations of Topiramate
Formulations of Mazindol
Application:
13/638,294 →
Publication:
US 2013/0011483
Formulations of Viloxazine
Methods of Producing Molindone and Its Salts
Method of Treatment of Aggression
Method of Treatment of Aggression
Application:
14/079,039 →
Publication:
US 2014/0135326
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Stabilized Formulations of Cns Compounds
Sustained-Release Formulations of Topiramate
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Sustained-Release Formulations of Topiramate
Drug Formulations Having Reduced Abuse Potential
Viloxazine Compositions
Methods of Producing Molindone and Its Salts
Sustained-Release Formulations of Topiramate
Method of Treatment of Attention Deficit/Hyperactivity Disorder (Adhd)
Application:
14/634,281 →
Publication:
US 2015/0290202
Method of Treatment of Cns Disorders
Application:
14/795,983 →
Publication:
US 2016/0136135
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Formulations of Mazindol
Application:
14/841,898 →
Publication:
US 2016/0008285
Osmotic Drug Delivery System
Formulations of Viloxazine
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
Formulations of Viloxazine
Methods for Producing Viloxazine Salts and Novel Polymorphs Thereof
Sustained-Release Formulations of Topiramate
Sustained-Release Formulations of Topiramate
Methods of Producing Molindone and Its Salts
Sustained-Release Formulations of Topiramate
Methods, System, and Kit for Monitoring, Diagnosing, and Treating Impulsive Aggression
Application:
15/499,357 →
Publication:
US 2017/0312289
Formulations of Viloxazine
Method of Treatment of Attention Deficit/Hyperactivity Disorder (Adhd)
Methods of Producing Molindone and Its Salts
Method of Treatment of Aggression
Related Assignments
(4)
Other recorded transfers of the patents in this record — the chain of ownership.
Release of Security Interest
Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
Confirmatory Grant of Security Interest in United States Patents
Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055845/0618 →
Confirmatory Grant of Security Interest in United States Patents
Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055846/0246 →
Release of Security Interest
Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC
Reel/Frame 067239/0795 →